Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pralsetinib versus standard of care in first-line RET fusion-positive metastatic non-small cell lung cancer
2019-002463-10Phase 3Unknown
- Sponsor
- Blueprint Medicines
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer (NSCLC) comparing Pralsetinib with Investigator's choice platinum-containing standard of care (2 arms). Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
pralsetinib
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2019-002463-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002463-10.